Overview

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Status:
Completed
Trial end date:
2018-04-19
Target enrollment:
Participant gender:
Summary
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions